)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Zevra Therapeutics
Zevra Therapeutics (ZVRA) investor relations material
Zevra Therapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary2 Jun, 2026
Mission and vision
Aims to redefine possibilities in rare disease therapeutics, focusing on patient-centric innovation and accountability.
Seeks to make a transformational impact through insights from patients and a culture of integrity and courage.
Portfolio and pipeline
Offers commercial-stage rare disease products and late-stage clinical assets, including MIPLYFFA for NPC and OLPRUVA for UCD.
Arimoclomol (MIPLYFFA) approved by FDA in 2024 for NPC, with EU MAA under review and IP protection through 2031.
Celiprolol in Phase 3 for VEDS, with orphan drug and breakthrough therapy designations.
Financial performance and position
Generated $106.5M net revenue in 2025 and exited Q1 2026 with $236.8M in cash, cash equivalents, and investments.
Q1 2026 net income was $37.9M, with no debt and strong operational discipline.
Revenue sources include product sales, expanded access reimbursements, and licensing/royalty income.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zevra Therapeutics
- AI-driven patient identification and global expansion fuel growth and pipeline acceleration.ZVRA
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Q1 2026 net income hit $37.9M, revenue rose 78%, and debt was eliminated.ZVRAQ1 20266 May 2026
- Shareholders to vote on board declassification, director elections, and auditor ratification.ZVRAProxy filing20 Apr 2026
- Record revenue, foundational NPC therapy, and advancing VEDS pipeline fuel rare disease growth.ZVRACorporate presentation13 Apr 2026
- Proposals cover director elections, auditor ratification, and Board declassification.ZVRAProxy filing6 Apr 2026
- MIPLYFFA drives growth as a foundational NPC therapy, fueling expansion and pipeline innovation.ZVRACorporate presentation16 Mar 2026
- MIPLYFFA drives rare disease growth with strong revenue, global expansion, and pipeline progress.ZVRAThe Citizens Life Sciences Conference 202611 Mar 2026
- FY 2025 net income was $83.2M on $106.5M revenue, driven by MIPLYFFA's strong growth.ZVRAQ4 20259 Mar 2026
- Strong rare disease portfolio, rapid product uptake, and robust financial position drive growth.ZVRATD Cowen 45th Annual Healthcare Conference3 Feb 2026
Next Zevra Therapeutics earnings date
Q2 202611 Aug, 2026
Zevra Therapeutics
Next Zevra Therapeutics earnings date
Q2 202611 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage